The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
107538412 10753841 2 F 20131206 20160829 20150202 20160901 EXP FR-ROCHE-1350320 ROCHE GIRAUD C, TATAR Z AND SOUBRIER M AGRANULOCYTOSIS UNDER BIOTHERAPY IN RHEUMATOID ARTHRITIS: THREE CASES HYPOTHESIS OF PARVOVIRUS B19 INVOLVEMENT IN AGRANULOCYTOSIS OBSERVED UNDER TOCILIZUMAB AND RITUXIMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS. CLINICAL RHEUMATOLOGY 2016 AUG 19;:1-4. 53.00 YR F Y 0.00000 20160901 MD FR FR

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
107538412 10753841 1 PS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) Y 103705 1 G SOLUTION FOR INFUSION QD
107538412 10753841 2 SS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) Y 103705 1 G SOLUTION FOR INFUSION QD
107538412 10753841 3 SS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) Y 103705 1 G SOLUTION FOR INFUSION QD
107538412 10753841 4 SS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) 4TH CYCLE Y 103705 1 G SOLUTION FOR INFUSION QD
107538412 10753841 5 SS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) DAY 15 OF 4TH CYCLE Y 103705 1 G SOLUTION FOR INFUSION QD
107538412 10753841 6 SS MABTHERA RITUXIMAB 1 Intravenous (not otherwise specified) Y 103705 SOLUTION FOR INFUSION
107538412 10753841 7 SS Tocilizumab TOCILIZUMAB 1 Unknown 125276
107538412 10753841 8 SS METOJECT METHOTREXATE SODIUM 1 Subcutaneous Y 0 15 MG QD
107538412 10753841 9 SS PLAQUENIL HYDROXYCHLOROQUINE SULFATE 1 Oral Y 0 200 MG QD
107538412 10753841 10 C LEVOTHYROX LEVOTHYROXINE 1 Oral 0
107538412 10753841 11 C SPECIAFOLDINE FOLIC ACID 1 Oral 0
107538412 10753841 12 C UVEDOSE CHOLECALCIFEROL 1 Oral TREATMENT DURATION = 1 DAY 0
107538412 10753841 13 C SOLU-MEDROL METHYLPREDNISOLONE SODIUM SUCCINATE 1 Unknown 0
107538412 10753841 14 C HUMIRA ADALIMUMAB 1 Unknown 0
107538412 10753841 15 C ENBREL ETANERCEPT 1 Unknown 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
107538412 10753841 1 Rheumatoid arthritis
107538412 10753841 7 Rheumatoid arthritis
107538412 10753841 8 Rheumatoid arthritis
107538412 10753841 9 Rheumatoid arthritis
107538412 10753841 10 Hypothyroidism

Outcome of event

Event ID CASEID OUTC COD
107538412 10753841 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
107538412 10753841 Agranulocytosis
107538412 10753841 Leukopenia
107538412 10753841 Thrombocytopenia
107538412 10753841 Treatment failure

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
107538412 10753841 1 201203 0
107538412 10753841 2 201210 0
107538412 10753841 3 201304 0
107538412 10753841 4 20131122 20131122 0
107538412 10753841 5 20131206 20131206 0
107538412 10753841 6 201211 0
107538412 10753841 7 2011 0
107538412 10753841 8 2005 20131206 0
107538412 10753841 9 201302 20131206 0
107538412 10753841 13 20131122 0
107538412 10753841 14 2005 2011 0
107538412 10753841 15 2011 2012 0